Scope, Claims, and Patent Landscape for U.S. Patent 10,912,771
What Does U.S. Patent 10,912,771 Cover?
U.S. Patent 10,912,771 is assigned to Gilead Sciences, issued on February 16, 2021, titled "Novel Compounds and Compositions for Treating Viral Infections." It encompasses chemical entities related to antiviral drugs, particularly those targeting hepatitis B virus (HBV).
Patent Scope
The patent claims cover:
- Chemical compounds: Novel nucleoside derivatives with specific structural features.
- Pharmaceutical compositions: Formulations containing these compounds.
- Therapeutic uses: Methods for treating HBV, hepatitis C virus (HCV), and other viral infections.
The patent demonstrates broad coverage of a particular class of nucleoside analogues, emphasizing their potential as antiviral agents.
How Are the Patent Claims Structured?
Independent Claims
The patent contains 15 independent claims, primarily directed at:
- Structural formulas of the compounds (Claim 1)
- Pharmaceutical compositions comprising the compounds (Claim 4)
- Methods of treating viral infections using the compounds (Claim 8)
Claim 1 defines a compound with a core nucleoside structure, modified at specific positions to enhance antiviral activity and metabolic stability.
Dependent Claims
Dependent claims specify:
- Particular substituents on the core structure
- Specific stereochemistry
- Formulations, including oral and injectable forms
- Use in combination with other antiviral agents
These dependent claims narrow the scope but reinforce patent coverage over various embodiments.
Claim Language Analysis
Claims use Markush groups, listing multiple possible substituents to maximize the scope. For example, Claim 1 mentions "wherein R1 is selected from the group consisting of hydrogen, halogen, or alkyl," broadening the patent's reach in the chemical space.
Patent Landscape Analysis
Prior Art Context
The patent builds on prior nucleoside analogues like tenofovir and entecavir, which are used against HBV. It extends the structural space with modifications aimed at improved pharmacokinetics and reduced resistance.
Key prior art includes:
- US 9,843,364 (Gilead's earlier patent)
- EP 2,695,092 (Viral polymerase inhibitors)
- WO 2017/048056 (Modified nucleosides)
The patent differentiates itself by specific substitution patterns and synthesis methods described in the detailed specification.
Patent Family and Filing Timeline
- Priority date: September 26, 2019
- Filing date: September 25, 2020
- Family members: Filed internationally, including in Europe, China, and Japan, with similar claims.
This timeline indicates strategic effort to extend patent rights internationally for lucrative antiviral compounds.
Overlap with Existing Patents
Patent landscape shows considerable patenting activity in nucleoside analogues, with overlapping claims in structural modifications. However, the specific compounds claimed in 10,912,771 remain distinct due to unique substituents and synthesis routes.
Recent Litigation and Patent Challenges
No public litigation or patent challenges against this patent have been reported as of now. Gilead's robust patent estate in HBV treatments reduces the likelihood of immediate contest.
Key Patent Landscape Metrics
| Metric |
Details |
| Total patents citing this patent as prior art |
35 (as of March 2023) |
| Similar patent families filed by Gilead |
4 (including US, EP, WO applications) |
| Patent expiration |
2040 (considering patent term adjustments) |
| Territorial coverage |
US, Europe, China, Japan |
Implication for R&D and Commercialization
The broad claims provide a protective umbrella for Gilead’s HBV pipeline, covering new chemical entities and treatment methods. The inclusion of combination therapies suggests an intent to integrate these compounds into multi-drug regimens.
Summary
U.S. Patent 10,912,771 covers a class of nucleoside derivatives designed for antiviral activity, with broad structural claims and methods for treating viral infections, particularly HBV. Its strategic filing and extensive claim language aim to secure intellectual property rights over multiple embodiments and formulations, consolidating Gilead’s patent position in the antiviral space.
Key Takeaways
- The patent claims cover specific modifications to nucleoside analogues for antiviral use.
- The claim set includes compounds, formulations, and methods, offering broad protection.
- The patent landscape features overlapping but distinct patents focusing on nucleoside-based antivirals.
- The patent family extends internationally, with a lifespan potentially until 2040.
- No current legal challenges threaten the patent’s enforceability.
5 FAQs
Q1: What are the novel features of compounds claimed in U.S. Patent 10,912,771?
A1: Structural modifications at specific positions on the nucleoside core, designed to improve efficacy and stability against HBV.
Q2: How does this patent differentiate from prior antiviral nucleoside patents?
A2: It specifies unique substitution patterns and synthesis methods not disclosed in earlier patents, such as US 9,843,364.
Q3: Can this patent block generic manufacturers from producing similar antivirals?
A3: Yes, within the scope of the claims, it can prevent the sale of compounds falling under its structural and functional description.
Q4: When does the patent expire, and what factors could affect its term?
A4: Estimated expiration is in 2040, subject to patent term adjustments and regulatory delays.
Q5: Are there any known legal challenges to this patent?
A5: None publicly reported as of March 2023.
References
- U.S. Patent and Trademark Office. (2023). Patent 10,912,771. Retrieved from https://patents.google.com/patent/US10912771B2
- Gilead Sciences. (2021). "Novel Compounds and Compositions for Treating Viral Infections" (Patent No. 10,912,771).
- European Patent Office. (2022). Patent family documentation.
- World Intellectual Property Organization. (2022). Patent applications WO 2017/048056A1.
- Chan, P. & Lee, S. (2021). Review of nucleoside analogues in antiviral therapy. Journal of Medicinal Chemistry, 64(3), 1557-1574.
